Zaid Yaqoob, MD
Pulmonary Disease · Flint, MINPI 1386185684
Payments from drug & device makers
Across 66 payments — averaging $67.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- AstraZeneca$514
- GSK$297
- Regeneron Healthcare Solutions, Inc.$187
- Sanofi$104
- Boston Scientific$94
- plus $510 from 15 others
What the payments were for
- Travel & lodging$2,11448%
- Food & beverage$2,29452%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 13 | $2,719 |
| AstraZeneca | 11 | $514 |
| GSK | 13 | $297 |
| Regeneron Healthcare Solutions, Inc. | 4 | $187 |
| Sanofi | 1 | $104 |
| Boston Scientific | 1 | $94 |
| Insmed, Inc. | 3 | $69 |
| Harmony Biosciences LLC | 2 | $57 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Merck | 2 | $44 |
| Pfizer | 2 | $41 |
| Boehringer Ingelheim | 2 | $39 |
| Verona Pharma, Inc. | 2 | $33 |
| Ionis Pharmaceuticals, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| United Therapeutics Corporation | 1 | $23 |
| Pulmonx Corporation | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,425 in reported general payments places this provider in the 60th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Flint
- John YoussefFlint$92K
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.